Drug Profile
Research programme: cancer therapeutics - Seelos Therapeutics
Alternative Names: DDAIP-Taxol; Fluorouracil - Seelos Therapeutics; Paclitaxel - Seelos Therapeutics; Rituximab - Seelos TherapeuticsLatest Information Update: 29 Jan 2019
Price :
$50
*
At a glance
- Originator Apricus Bioscience
- Developer Apricus Biosciences
- Class
- Mechanism of Action Angiogenesis inhibitors; CD20 antigen inhibitors; DNA synthesis inhibitors; Immunosuppressants; Thymidylate synthase inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Actinic keratosis; Non-Hodgkin's lymphoma; Orofacial cancer
Most Recent Events
- 25 Jan 2019 Seelos Therapeutics merged with Apricus Biosciences to form Seelos Therapeutics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Actinic keratosis in USA (Topical)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA (SC)